Publications by authors named "J M Trevejo"
Article Synopsis
- The study aims to assess the safety and effectiveness of lotilaner ophthalmic solution 0.25% in treating Demodex blepharitis compared to a placebo (vehicle).
- In a randomized, double-masked clinical trial involving 412 participants, patients were split into two groups: one receiving lotilaner and the other receiving a vehicle without the active ingredient, over 6 weeks.
- Results showed that the lotilaner group had significantly better outcomes in terms of collarette cure, mite eradication, and associated symptoms compared to the control group, indicating its efficacy in treating the condition.
Influenza A infections cause significant seasonal morbidity and mortality as well as periodic pandemic infections. Currently, no approved therapies exist for patients hospitalized with influenza. The efficacy of VIS410, a broadly neutralizing human immunoglobulin IgG1 monoclonal antibody engineered to bind to the stem region of group 1 and 2 influenza A hemagglutinins, was explored in experimental human influenza infection.
View Article and Find Full Text PDFBackground: VIS410, a broadly neutralizing monoclonal antibody that binds the hemagglutinin stem of influenza A viruses, was safe and efficacious in a human H1N1 virus challenge study. This study evaluated the safety and tolerability of VIS410 in non-hospitalized adult patients with uncomplicated influenza A.
Methods: Patients 18 to 65 years of age with symptom onset within 72 h were randomized 1:1:1 to receive a single intravenous infusion of VIS410 4000 mg, 2000 mg, or placebo.
Background: Pimodivir (formerly JNJ-63623872) is a novel, non-nucleoside polymerase complex inhibitor with in vitro activity against influenza A virus, including pandemic 2009 H1N1, H7N9, H5N1 strains as well as neuraminidase- and amantadine-resistant strains.
Methods: Randomized, double-blind, placebo-controlled, Phase IIa study. Healthy volunteers (n=104) were inoculated with an influenza A/Wisconsin/67/2005 (H3N2) challenge virus.